Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 13/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17515222 | 0.84 | HTR6 (0.75) | HTR6CYP3A4ADRA2ACYP2D6ADRA2C | |
| SCHEMBL18134785 | 0.83 | HTR6 (0.72) | HTR6CYP3A4ADRA2ACYP2D6ADRA2C | |
| SCHEMBL19396331 | 0.82 | HTR6 (0.57) | KDM4EALDH1A1HTR6CYP3A4ADRA2A | |
| SCHEMBL376336 | 0.82 | ALDH1A1 (0.60) | KDM4EALDH1A1KDM1AMMP1MMP9 | |
| SCHEMBL19396330 | 0.80 | HTR6 (0.66) | KDM4EALDH1A1HTR6CYP3A4ADRA2A | |
| SCHEMBL23925168 | 0.79 | ALDH1A1 (0.51) | KDM4EALDH1A1KDM1AMMP1MMP9 | |
| SCHEMBL20629394 | 0.77 | HTR6 (0.60) | HTR6CYP3A4ADRA2ACYP2D6ADRA2C | |
| SCHEMBL20629070 | 0.76 | HTR6 (0.42) | KDM4EALDH1A1HTR6CYP3A4ADRA2A | |
| SCHEMBL28569013 | 0.74 | VEGFA (0.69) | KDM4EALDH1A1KDM1AMMP1MMP9 | |
| SCHEMBL18983290 | 0.73 | MTNR1B (0.57) | KDM4EALDH1A1MMP1MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010527-B2 | Active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite | SUVEN SCIENCES LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| US-20170273944-A1 | ACTIVE METABOLITE OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE AND DIMESYLATE DIHYDRATE SALT OF ACTIVE METABOLITE | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273944-A1 | ACTIVE METABOLITE OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE AND DIMESYLATE DIHYDRATE SALT OF ACTIVE METABOLITE | HTR6, HTR5A, HTR1A | KDM4E 1117/4885ALDH1A1 320/4885HTR6 1/4885 |
| US-10010527-B2 | Active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite | HTR6, HTR5A, HTR1A | KDM4E 1117/4885ALDH1A1 320/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.